These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32996106)

  • 1. Update of EMA's Guideline on the Environmental Risk Assessment (ERA) of Medicinal Products for Human Use.
    Wess RA
    Ther Innov Regul Sci; 2021 Mar; 55(2):309-323. PubMed ID: 32996106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001.
    Straub JO
    Toxicol Lett; 2002 Oct; 135(3):231-7. PubMed ID: 12270681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001.
    Straub JO
    Toxicol Lett; 2002 May; 131(1-2):137-43. PubMed ID: 11988366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of measured and predicted environmental concentrations of selected human pharmaceuticals and personal care products.
    Liebig M; Moltmann JF; Knacker T
    Environ Sci Pollut Res Int; 2006 Mar; 13(2):110-9. PubMed ID: 16612900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical review on the Environmental Risk Assessment of medicinal products for human use in the centralised procedure.
    Caneva L; Bonelli M; Papaluca-Amati M; Vidal JM
    Regul Toxicol Pharmacol; 2014 Apr; 68(3):312-6. PubMed ID: 24447908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the regulatory environmental risk assessment of human pharmaceuticals: Required changes in the new legislation.
    Gildemeister D; Moermond CTA; Berg C; Bergstrom U; Bielská L; Evandri MG; Franceschin M; Kolar B; Montforts MHMM; Vaculik C
    Regul Toxicol Pharmacol; 2023 Aug; 142():105437. PubMed ID: 37354938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experiences with the OECD 308 transformation test: a human pharmaceutical perspective.
    Ericson JF; Smith RM; Roberts G; Hannah B; Hoeger B; Ryan J
    Integr Environ Assess Manag; 2014 Jan; 10(1):114-24. PubMed ID: 23794155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory Acceptance of Alternative Methods in the Development and Approval of Pharmaceuticals.
    Beken S; Kasper P; van der Laan JW
    Adv Exp Med Biol; 2016; 856():33-64. PubMed ID: 27671719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of the OECD 308 water/sediment systems for investigating the biodegradation of pharmaceuticals.
    Ericson JF
    Environ Sci Technol; 2007 Aug; 41(16):5803-11. PubMed ID: 17874790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the OECD 314B activated sludge die-away test for assessing the biodegradation of pharmaceuticals.
    Ericson JF
    Environ Sci Technol; 2010 Jan; 44(1):375-81. PubMed ID: 19961217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
    Dejas-Eckertz P; Schäffner G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges of Regulatory Environmental Risk Assessment for Human Pharmaceuticals with Focus on Antibiotics.
    Wess RA; Schmidt T; Höger S
    Chimia (Aarau); 2020 Mar; 74(3):183-191. PubMed ID: 32197678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Environmental risk assessment of advanced therapies containing genetically modified organisms in the EU.
    Whomsley R; Palmi Reig V; Hidalgo-Simon A
    Br J Clin Pharmacol; 2021 Jun; 87(6):2450-2458. PubMed ID: 33600022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceuticals in the environment: scientific evidence of risks and its regulation.
    Küster A; Adler N
    Philos Trans R Soc Lond B Biol Sci; 2014 Nov; 369(1656):. PubMed ID: 25405974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranking of concern, based on environmental indexes, for pharmaceutical and personal care products: an application to the Spanish case.
    Ortiz de García S; Pinto GP; García-Encina PA; Irusta Mata RI
    J Environ Manage; 2013 Nov; 129():384-97. PubMed ID: 23995140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the step-wise tiered approach for ERA of pharmaceuticals useful for the assessment of cancer therapeutic drugs present in marine environment?
    Aguirre-Martínez GV; Okello C; Salamanca MJ; Garrido C; Del Valls TA; Martín-Díaz ML
    Environ Res; 2016 Jan; 144(Pt A):43-59. PubMed ID: 26555843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Environmental risk assessment of pharmaceutical drug substances--conceptual considerations.
    Länge R; Dietrich D
    Toxicol Lett; 2002 May; 131(1-2):97-104. PubMed ID: 11988362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.